Karmanos Cancer Institute | Strategic Alliance Partners

March 22, 2023

Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

March 22, 2023

Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.

March 22, 2023

Key opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.

March 03, 2023

Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.

March 03, 2023

Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.

February 13, 2023

The Barbara Ann Karmanos Cancer Institute is now seeing patients at the new Karmanos Cancer Institute – Roseville.

September 26, 2022

Dr Deol discusses what he wants his trainees to take from the fellowship program he directs, how his colleagues help fellows find jobs, and how he helps fellows deal with grief.

September 14, 2022

Abhinav Deol, MD, discusses how Karmanos Cancer Institute prepares trainees for their first job and helps them handle negative situations and deal with grief.

August 20, 2022

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

May 30, 2022

Drs Mamdani, Assad, and Robinette discuss the changes in the culture of oncology today compared with when they first started their careers, the challenges they experienced along the way, and advice they would share with up-and-coming oncologists based on what they know now.

May 26, 2022

Jay Yang, MD, discusses the current treatment landscape of mantle cell lymphoma.

May 20, 2022

Abhinav Deol, MD, discusses the importance of communication and collaboration in CAR T-cell therapy.

May 03, 2022

Abhinav Deol, MD, discusses shifting CAR T-cell therapy to earlier lines of therapy in cancer care.

April 21, 2022

Hadeel Assad, MD, discussed how CDK4/6 inhibitors have been implemented into practice and provided updates on key clinical trials in HER2-positive breast cancer and triple-negative breast cancer.

February 09, 2022

Jeffrey Zonder, MD, discusses his presentation at the 2021 ASH Annual Meeting on the impact of the phase 1/2 study utilizing REGN5458 in multiple myeloma.

October 12, 2021

Across the paradigms of leukemias and lymphomas, novel therapies—such as BTK inhibitors, PI3K inhibitors, time-limited therapies, and even CAR T-cell therapies—have transformed the treatment of patients and prolonged survival without the need for chemotherapy.